Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370521 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
A Phase 2 study, sponsored by Spruce Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT05370521 is a Phase 2 study that was terminated before completion, run by Spruce Biosciences. The registered enrollment target is 27 participants.
The verdict
NCT05370521, a Phase 2 study, was terminated before completion, sponsored by Spruce Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
Interventions
- DRUG Placebo
- DRUG Tildacerfont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05370521
The ClinicalTrials.gov registry entry for NCT05370521 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spruce Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05370521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05370521 about?
NCT05370521 is a clinical study titled "A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens". An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
What is the current status of trial NCT05370521?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-05-15. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05370521?
The interventions under investigation include: Placebo (DRUG), Tildacerfont (DRUG).
Who is sponsoring clinical trial NCT05370521?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.